Management of Patients With Thalassemia Minor and Breast Cancer at CardioOncology Outpatient Clinics: Age Quod Agis (AQUA)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Incidence of any rise in troponin
研究概览
简要总结
This retrospective study aimed to evaluate the demographic characteristics, clinical conditions in term of physical examination findings), functional status, and laboratory results of patients with thalassemia minor (TM) and breast cancer (BC) in order to identify any differences between the group with BC only.
Available data as anticancer treatment, comorbidities, weight and height will be combined to report body mass index (BMI) in kg/m2, systolic and diastolic blood pressure, heart rate, ECG, transthoracic echocardiography, blood count, lipid panels, glucose, kidney function tests, (N terminal) NT-proBNP, troponins, handgrip assessments, functional status were extracted from patients files and hospital electronic archives.
详细描述
Following data was extracted from files and hospital electronic records, and will be evaluated (at baseline, 3, 6, 9 and 12 months):
- Physical examination findings (as pretibial edema, jugular venous distension, lung rales),
- Clinically significant changes in cardiac function as determined by Left Ventricular Ejection Fraction (LVEF) measurements using transthoracic echocardiography,
- Any changes in (N terminal) NT-ProBNP and troponin,
- Any changes in manual handgrip measurements for both hands using hydraulic hand dynamometer,
- Applied medications,
were extracted and will be evaluated.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosis of breast cancer, and thalassemia minor,
- •>18 years old,
- •Referred by oncologist for cardiac evaluation.
- •Patients with available cardiac evaluations data at baseline and during breast cancer treatment
排除标准
- •Patients without diagnosis of breast cancer, and thalassemia minor,
- •<18 years old,
- •Patients without any cardiac evaluations at baseline, and during cancer treatment.
- •Patients with history of any cardiotoxic treatment prior to enrolment.
结局指标
主要结局
Incidence of any rise in troponin
时间窗: From enrollment to 12 months
Troponin results from baseline and at 3, 6 and 12 months of cancer treatment .
Incidence of any rise in NT-ProBNP
时间窗: From enrollment to 12 months
NT-ProBNP results from baseline and at 3, 6 and 12 months of cancer treatment .
Incidence of any reduction in LV
时间窗: From enrollment to 12 months
Echocardiographic measurements of Left ventricle (LV) ejection fraction from baseline and at 3, 6 and 12 months of cancer treatment.
次要结局
未报告次要终点
研究者
Cafer Zorkun
Associate Professor
Istanbul University